Pilot & Feasibility Studies 2022 September 3 [Link] Anna C Bibby, Natalie Zahan-Evans, Emma Keenan, Charles Comins, John E Harvey, Helen Day, Najib M Rahman, Janet E Fallon, Rachael Gooberman-Hill, Nick A Maskell Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy with a poor prognosis. Systemic immunotherapy is an effective frontline treatment…

Read More

Molecular Oncology 2022 August 28 [Link] Hoa-Le Mai, Sophie Deshayes, Thi-Van-Ha Nguyen, Virginie Dehame, Anne-Laure Chéné, Sophie Brouard, Christophe Blanquart Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer mainly related to asbestos exposure. Despite recent therapeutic advances, notably immunotherapies, the benefit remains limited and restricted to a small percentage of patients. Thus, a better…

Read More

Clinical Cancer Research 2022 August 22 [Link] Amanda M Nash, Samira Aghlara-Fotovat, Bertha Castillio, Andrea Hernandez, Aarthi Pugazenthi, Hyun-Sung Lee, Hee-Jin Jang, Annie Nguyen, Alexander Lu, Bryan M Burt, Ravi K Ghanta, Omid Veiseh Abstract Purpose: Interleukin-2 (IL-2) immunotherapy has the potential to elicit immune-mediated tumor lysis via activation of effector immune cells, but clinical…

Read More

Frontiers in Public Health 2022 July 22 [Link] Zhuo-Miao Ye, Zi-Qing Tang, Zhe Xu, Qin Zhou, Huan Li Abstract Background: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study…

Read More

BioMed Research International 2022 July 27 [Link] M Shobana, V R Balasraswathi, R Radhika, Ahmed Kareem Oleiwi, Sushovan Chaudhury, Ajay S Ladkat, Mohd Naved, Abdul Wahab Rahmani Abstract Cancer of the mesothelium, sometimes referred to as malignant mesothelioma (MM), is an extremely uncommon form of the illness that almost always results in death. Chemotherapy, surgery,…

Read More

Targeted Oncology 2022 July [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in…

Read More

Targeted Oncology 2022 July 30 [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos…

Read More

JTO Clinical and Research Reports 2022 June 9 [Link] Takaaki Tanaka, Shoji Asakura, Kazuya Hisamatsu, Nobukazu Fujimoto Abstract A 69-year-old man presented with a pulmonary opacity at a regular medical check-up. He had been exposed to asbestos in a chemical fiber manufacturing setting. Result of positron emission tomography with computed tomography (CT) revealed fluorodeoxyglucose accumulations…

Read More

Nature Reviews. Clinical Oncology. 2022 July 1 [Link] Dean A Fennell, Sean Dulloo, James Harber Abstract Over the past decade, immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. In mesothelioma, a rare cancer with a dismal prognosis generally caused by exposure to asbestos, treatment with single or dual ICIs results in robust improvements in…

Read More